Letters

;

HIV/AIDS groups letter in support of MassHealth making injectable long-acting PrEP available without barriers

Aug 29, 2022

HIV/AIDS groups are concerned that MassHealth (Massachusetts Medicaid) has not yet added cabotegravir, a new long-acting injectable form of pre-exposure prophylaxis (PrEP) to prevent HIV, to its formulary. We urge MassHealth to make sure injectable long-acting cabotegravir as PrEP is available on formulary without any barriers to access, such as utilization management or prior authorization requirements.

read more

64 organizations request expedited Medicare National Coverage Determination for long-acting injectable PrEP

Aug 5, 2022

We are pleased that the Centers for Medicare and Medicaid Services (CMS) has accepted a request for a National Coverage Determination (NCD) for cabotegravir, a new long-acting injectable form of pre-exposure prophylaxis (PrEP) to prevent HIV.  A National Coverage Determination is the only pathway to coverage under Medicare Part B for a provider-administered drug.  We have, however, been disappointed to learn that CMS has given no timeline for action on this National Coverage Determination, which will make this new long-acting PrEP medication out of reach for potential PrEP users.  Combined with a USPSTF recommendation, an NCD will also make the drug available to Medicare Part B beneficiaries without cost-sharing, thus eliminating one of the biggest barriers to PrEP uptake.

read more

Support for New York’s S.5299-A/A.1741-A on copay assistance

Jul 18, 2022

The HIV+Hepatitis Policy Institute is a leading HIV and hepatitis policy organization promoting quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions. We strongly support S.5299-A/A.1741-A, which would require health insurers to accept and count payments made on behalf of patients towards deductibles and out-of-pocket maximums. We urge you to sign this legislation into law as soon as possible.

read more

Solutions to improve COVID-19 vaccine access & protect intellectual property

Jun 8, 2022

On behalf of the patients we serve who are living with HIV, hepatitis, cancer, lupus, autoimmune diseases, and other serious chronic and complex conditions, we write to share recommendations to address global COVID-19 vaccine equity and access barriers. While we commend the World Trade Organization (WTO) and the Office of the United States Trade Representative for prioritizing efforts to improve vaccine access, it must not come at the expense of waiving intellectual property (IP) protections.  To do so would have unprecedented effects on future medical development.

read more

Letter in support of HIV and hepatitis provisions in the “Restoring Hope for Mental Health and Well-Being Act of 2022” (H.R. 7666)

May 10, 2022

The HIV+Hepatitis Policy Institute, a national, non-profit organization whose mission is to promote quality and affordable healthcare for people living with or at risk of HIV, hepatitis, and other serious and chronic health conditions, is pleased to offer comments in support of the HIV and viral hepatitis provisions included in the “Restoring Hope for Mental Health and Well-Being Act of 2022” (HR 7666). This bipartisan bill introduced by Chairman Frank Pallone and Ranking Member Cathy McMorris Rodgers reauthorizes key Substance Abuse and Mental Health Services Administration (SAMHSA) and Health Resources and Services Administration (HRSA) programs to address the national mental health and substance use disorder crises. The subcommittee is expected to consider the bill tomorrow.

read more

Search

Categories

Tags

ACA Appropriations Biden administration CDC co-pay accumulators Congress copay copay accumulator Copay accumulators Copay assistance Cost-sharing COVID-19 Drug Pricing FDA Gay men healthcare Hepatitis Hepatitis B hepatitis C Hepatitis Prevention HHS HIV HIV Prevention Insurers Medicaid medicare Medicare Part D NAIC NIH PBM PBMs PrEP Prescription Drugs Private Insurance Ryan White Program state STDs Syringe services Testing transparency Treatment Trump administration women

Recent Testimony, Letters, Comments

Pin It on Pinterest